trending topics
market reports
- 
  MEDICAL JAPAN 2025 OSAKA Returns to Showcase Global Innovations2025-02-17 
- 
  Visit MEDICAL JAPAN 2023 TOKYO and take full advantage of the business opportunities!2023-09-01 
- 
  US to distribute 400 million free N95 masks at CVS, Walgreens in COVID fight2022-01-21 
- 
  Ethiopia receives additional 2.2 mln doses of Chinese-donated COVID-19 vaccines2022-01-21 
- 
  Hong Kong researchers say they develop novel material able to kill COVID-19 virus2022-01-14 
- 
  10 million more Chinese doses on way for Kenya2022-01-14 
- 
  Sino-African ties on track for a brighter future2022-01-07 
- 
  Efforts urged to boost COVID-19 vaccine production capacity in poor countries2022-01-07 
- 
  UAE approves Sinopharm's new protein-based COVID-19 vaccine2022-01-07 
- 
  UAE approves Sinopharm's new protein-based COVID-19 vaccine2022-01-07 
22 COVID-19 vaccines enter clinical trials in China: health official
2021-07-09
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
 
(China Daily)
                                label :
                                
                            
                            
                         
               
               
               My Member
My Member Message Center
Message Center 
                 
               
                 
                         
                             
                     
                 
             
                     
                     
                     
                     
                    